Skip to main content
NVDA+0.36%AAPL-0.03%GOOGL-0.61%MSFT+0.12%AMZN+0.11%TSM+0.96%SPCX+5.15%META+0.11%AVGO+0.07%TSLA+0.08%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.45%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.78%NZDUSD-1.70%AUDUSD-1.19%EURUSD-1.17%USDCHF+1.15%GBPUSD-1.09%USDTHB+1.06%CADJPY+0.96%NZDCAD-0.88%USDCAD+0.85%CHFJPY+0.74%GBPJPY+0.65%GBPNZD+0.62%AUDJPY+0.59%EURJPY+0.58%NZDCHF-0.57%EURNZD+0.55%AUDNZD+0.53%GBPTRY+0.41%EURCAD-0.37%AUDCAD-0.35%GBPHKD+0.32%USDTRY+0.32%CADCHF+0.31%GBPMXN-0.28%GBPCAD-0.27%USDILS+0.16%GBPAUD+0.08%USDCNH+0.07%NZDJPY+0.07%USDZAR+0.06%AUDSGD-0.05%NZDMXN+0.05%SGDJPY+0.05%GBPSGD-0.05%EURGBP-0.05%USDCOP-0.04%AUDCHF-0.04%EURAUD+0.04%USDMXN+0.04%EURSGD-0.03%GBPCHF+0.03%USDHKD+0.02%USDSGD-0.02%NZDSGD+0.02%CHFSGD-0.01%EURCHF-0.01%EURPLN0.00%EURSEK0.00%GBPZAR0.00%PLNJPY0.00%USDSEK0.00%EURNOK0.00%EURDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%NOKJPY0.00%USDPLN0.00%EURCZK0.00%CHFNOK0.00%USDNOK0.00%USDDKK0.00%XPTUSD+0.51%USOIL-0.29%XNGUSD+0.23%GAGUSD-0.09%XAGUSD-0.09%GAUUSD-0.07%XAUUSD-0.07%HG1+0.02%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.31%ETHUSD-0.01%USDTUSD+0.01%XRPUSD+0.43%SOLUSD+1.18%TRXUSDT+1.00%ZECUSDT+19.13%DOGEUSD+0.51%XMRUSDT-3.59%LINKUSD+0.14%XLMUSD+2.39%BCHUSDT+0.68%UNIUSD+1.04%LTCUSD-0.03%TONUSD+29.54%HBARUSDT-1.61%SUIUSD+2.58%TAOUSDT+0.82%AAVEUSD-2.42%DOTUSDT+6.24%ICPUSDT+1.20%ONDOUSDT+3.17%WLDUSDT+1.83%ARBUSDT+7.40%ATOMUSDT-1.28%JUPUSDT-0.73%INJUSDT-1.11%STXUSDT+2.00%FETUSDT+3.07%PYTHUSDT-1.24%TIAUSDT+2.70%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.94%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+0.97%IOTAUSDT-0.78%AXSUSDT+0.14%FARTCOINUSDT-0.76%EOSUSDT-0.71%DYDXUSDT-0.20%ORDIUSDT+2.63%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%NVDA+0.36%AAPL-0.03%GOOGL-0.61%MSFT+0.12%AMZN+0.11%TSM+0.96%SPCX+5.15%META+0.11%AVGO+0.07%TSLA+0.08%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.45%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.78%NZDUSD-1.70%AUDUSD-1.19%EURUSD-1.17%USDCHF+1.15%GBPUSD-1.09%USDTHB+1.06%CADJPY+0.96%NZDCAD-0.88%USDCAD+0.85%CHFJPY+0.74%GBPJPY+0.65%GBPNZD+0.62%AUDJPY+0.59%EURJPY+0.58%NZDCHF-0.57%EURNZD+0.55%AUDNZD+0.53%GBPTRY+0.41%EURCAD-0.37%AUDCAD-0.35%GBPHKD+0.32%USDTRY+0.32%CADCHF+0.31%GBPMXN-0.28%GBPCAD-0.27%USDILS+0.16%GBPAUD+0.08%USDCNH+0.07%NZDJPY+0.07%USDZAR+0.06%AUDSGD-0.05%NZDMXN+0.05%SGDJPY+0.05%GBPSGD-0.05%EURGBP-0.05%USDCOP-0.04%AUDCHF-0.04%EURAUD+0.04%USDMXN+0.04%EURSGD-0.03%GBPCHF+0.03%USDHKD+0.02%USDSGD-0.02%NZDSGD+0.02%CHFSGD-0.01%EURCHF-0.01%EURPLN0.00%EURSEK0.00%GBPZAR0.00%PLNJPY0.00%USDSEK0.00%EURNOK0.00%EURDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%NOKJPY0.00%USDPLN0.00%EURCZK0.00%CHFNOK0.00%USDNOK0.00%USDDKK0.00%XPTUSD+0.51%USOIL-0.29%XNGUSD+0.23%GAGUSD-0.09%XAGUSD-0.09%GAUUSD-0.07%XAUUSD-0.07%HG1+0.02%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.31%ETHUSD-0.01%USDTUSD+0.01%XRPUSD+0.43%SOLUSD+1.18%TRXUSDT+1.00%ZECUSDT+19.13%DOGEUSD+0.51%XMRUSDT-3.59%LINKUSD+0.14%XLMUSD+2.39%BCHUSDT+0.68%UNIUSD+1.04%LTCUSD-0.03%TONUSD+29.54%HBARUSDT-1.61%SUIUSD+2.58%TAOUSDT+0.82%AAVEUSD-2.42%DOTUSDT+6.24%ICPUSDT+1.20%ONDOUSDT+3.17%WLDUSDT+1.83%ARBUSDT+7.40%ATOMUSDT-1.28%JUPUSDT-0.73%INJUSDT-1.11%STXUSDT+2.00%FETUSDT+3.07%PYTHUSDT-1.24%TIAUSDT+2.70%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.94%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+0.97%IOTAUSDT-0.78%AXSUSDT+0.14%FARTCOINUSDT-0.76%EOSUSDT-0.71%DYDXUSDT-0.20%ORDIUSDT+2.63%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%
CP

Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ • Healthcare

$12.23
-$0.71 (-5.6%)
Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$13
Day Range$12.18 - $13.15
Avg. Volume (3M)818.7K
Market Cap$1B
52 Week Range
$5.72$26.95
Next EarningsIn 48 daysNov 3, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$54.1M
EPS (TTM)
-$0.64
ROA (TTM)
-22.62%
Current Ratio
16.16

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-7.1%Q1 2026-$0.15
-7.1%Q2 2026-$0.15
-19.4%Q3 2026-$0.19
Next

Nov 3

in 48 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -19.4%

Corvus Pharmaceuticals’ earnings missed expectations in the second fiscal quarter of 2026, with EPS of -$0.19 trailing the -$0.16 estimate by -$0.03; the company reported these preliminary results on August 6, 2026. Net income was a loss of about $18.0 million, down ~125% from roughly $8.0 million a year ago, as the period also produced operating income of around -$19.3 million. EPS was down ~90% from -$0.10 a year ago. Cash flow from operations was negative at about $15.4 million, reflecting ongoing spend across its immuno-oncology and related pipeline programs, including mupadolimab (CPI-006), CPI-818, and ciforadenant (CPI-444). For the next period, consensus calls for EPS of -$0.21.

View full earnings history

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on developing and commercializing immuno-oncology therapies. The company operates as a small-cap drug developer built around antibody and small-molecule candidates, with programs aimed at cancer as well as inflammatory and fibrotic disease pathways.

Name
Corvus Pharmaceuticals, Inc.
CEO
Richard A. Miller
Website
www.corvuspharma.com
Industry
Healthcare
Year Founded
2014
Employees
37

Today's Snapshot

AI-generated

CRVS closed 5.6% below yesterday's close, while its sector was flat.

Trading Volume

Below 10d avg (1.0M)

910.7K

vs S&P 500 Today

Strong Underperformance

-4.98%

Updated: September 16, 2026 at 20:02 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
CRVS is trading at 12.23 and exhibits clear short-term weakness as price is beneath most moving averages and momentum readings are negative; the CCI is deeply negative and RSI sits near oversold levels. MACD is also negative and trend strength is muted, while ATR shows elevated percentage volatility around 0.69 and on-balance volume is weak. Although Bollinger signals show recent bounce potential, the preponderance of momentum and moving-average signals supports a bearish stance. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$12.98 - $13.92
    Sell
  • RSI (14)31.52
    Neutral
  • Stochastic %K (14, 3, 3)11.54
    Buy
  • MACD Level (12, 26)-0.40
    Sell

Peers & Related Assets

ABSIAbsci Corporation
$8.04+1.3%
OLMAOlema Pharmaceuticals, Inc.
$9.73-0.5%
VSTMVerastem, Inc.
$7.32-0.3%
PRTAProthena Corporation plc
$8.24-1.1%
RGNXREGENXBIO Inc.
$7.98+0.4%
CMPXCompass Therapeutics, Inc.
$1.83-1.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.